{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:46:23Z","timestamp":1793130383260,"version":"4.5.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"19","license":[{"start":{"date-parts":[[2017,7,24]],"date-time":"2017-07-24T00:00:00Z","timestamp":1500854400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,7,24]],"date-time":"2017-07-24T00:00:00Z","timestamp":1500854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K05 DA031246"],"award-info":[{"award-number":["K05 DA031246"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["K21 GM000680"],"award-info":[{"award-number":["K21 GM000680"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s00213-017-4684-8","type":"journal-article","created":{"date-parts":[[2017,7,24]],"date-time":"2017-07-24T11:17:07Z","timestamp":1500895027000},"page":"2883-2895","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":104,"title":["Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA)"],"prefix":"10.1007","volume":"234","author":[{"given":"Matthew B.","family":"Young","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth D.","family":"Norrholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara M.","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Jovanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila A.M.","family":"Rauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collin M.","family":"Reiff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boadie W.","family":"Dunlop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara O.","family":"Rothbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard L.","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,24]]},"reference":[{"key":"4684_CR1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1101\/lm.024752.111","volume":"19","author":"AD Abraham","year":"2012","unstructured":"Abraham AD, Cunningham CL, Lattal KM (2012) Methylphenidate enhances extinction of contextual fear. Learn Mem (Cold Spring Harbor, NY) 19:67\u201372","journal-title":"Learn Mem (Cold Spring Harbor, NY)"},{"key":"4684_CR2","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00418-013-1081-1","volume":"139","author":"E Asan","year":"2013","unstructured":"Asan E, Steinke M, Lesch KP (2013) Serotonergic innervation of the amygdala: targets, receptors, and implications for stress and anxiety. Histochem Cell Biol 139:785\u2013813","journal-title":"Histochem Cell Biol"},{"key":"4684_CR3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.neuropharm.2012.11.027","volume":"67","author":"DT Balu","year":"2013","unstructured":"Balu DT, Turner JR, Brookshire BR, Hill-Smith TE, Blendy JA, Lucki I (2013) Brain monoamines and antidepressant-like responses in MRL\/MpJ versus C57BL\/6J mice. Neuropharmacology 67:503\u2013510","journal-title":"Neuropharmacology"},{"key":"4684_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0014-2999(88)90056-8","volume":"149","author":"G Battaglia","year":"1988","unstructured":"Battaglia G, Brooks BP, Kulsakdinun C, De Souza EB (1988) Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol 149:159\u2013163","journal-title":"Eur J Pharmacol"},{"key":"4684_CR5","doi-asserted-by":"crossref","first-page":"10494","DOI":"10.1523\/JNEUROSCI.19-23-10494.1999","volume":"19","author":"S Benmansour","year":"1999","unstructured":"Benmansour S, Cecchi M, Morilak DA, Gerhardt GA, Javors MA, Gould GG, Frazer A (1999) Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. J Neurosci 19:10494\u201310501","journal-title":"J Neurosci"},{"key":"4684_CR6","doi-asserted-by":"crossref","first-page":"6766","DOI":"10.1523\/JNEUROSCI.22-15-06766.2002","volume":"22","author":"S Benmansour","year":"2002","unstructured":"Benmansour S, Owens WA, Cecchi M, Morilak DA, Frazer A (2002) Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter. J Neurosci 22:6766\u20136772","journal-title":"J Neurosci"},{"key":"4684_CR7","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0022-3565(24)29267-3","volume":"299","author":"KA Berg","year":"2001","unstructured":"Berg KA, Stout BD, Maayani S, Clarke WP (2001) Differences in rapid desensitization of 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptor-mediated phospholipase C activation. J Pharmacol Exp Ther 299:593\u2013602","journal-title":"J Pharmacol Exp Ther"},{"key":"4684_CR8","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1080\/17470919.2016.1143026","volume":"11","author":"AK Bershad","year":"2016","unstructured":"Bershad AK, Weafer JJ, Kirkpatrick MG, Wardle MC, Miller MA, de Wit H (2016) Oxytocin receptor gene variation predicts subjective responses to MDMA. Soc Neurosci 11:592\u2013599","journal-title":"Soc Neurosci"},{"key":"4684_CR9","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1038\/npp.2015.157","volume":"40","author":"M Bocchio","year":"2015","unstructured":"Bocchio M, Fucsina G, Oikonomidis L, McHugh SB, Bannerman DM, Sharp T, Capogna M (2015) Increased serotonin transporter expression reduces fear and recruitment of parvalbumin interneurons of the amygdala. Neuropsychopharmacology 40:3015\u20133026","journal-title":"Neuropsychopharmacology"},{"key":"4684_CR10","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1037\/0735-7044.112.4.952","volume":"112","author":"TB Borowski","year":"1998","unstructured":"Borowski TB, Kokkinidis L (1998) The effects of cocaine, amphetamine, and the dopamine D1 receptor agonist SKF 38393 on fear extinction as measured with potentiated startle: implications for psychomotor stimulant psychosis. Behav Neurosci 112:952\u2013965","journal-title":"Behav Neurosci"},{"key":"4684_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/BF02761776","volume":"10","author":"PA Boyer","year":"1998","unstructured":"Boyer PA, Skolnick P, Fossom LH (1998) Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study Journal of molecular neuroscience : MN 10:219\u2013233","journal-title":"A quantitative in situ hybridization study Journal of molecular neuroscience : MN"},{"key":"4684_CR12","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3389\/fpsyt.2014.00088","volume":"5","author":"MA Briscione","year":"2014","unstructured":"Briscione MA, Jovanovic T, Norrholm SD (2014) Conditioned fear associated phenotypes as robust, translational indices of trauma-, stressor-, and anxiety-related behaviors. Frontiers Psychiatry 5:88","journal-title":"Frontiers Psychiatry"},{"key":"4684_CR13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.neuroscience.2013.05.050","volume":"247","author":"NS Burghardt","year":"2013","unstructured":"Burghardt NS, Bauer EP (2013) Acute and chronic effects of selective serotonin reuptake inhibitor treatment on fear conditioning: implications for underlying fear circuits. Neuroscience 247:253\u2013272","journal-title":"Neuroscience"},{"key":"4684_CR14","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.biopsych.2012.10.012","volume":"73","author":"NS Burghardt","year":"2013","unstructured":"Burghardt NS, Sigurdsson T, Gorman JM, McEwen BS, LeDoux JE (2013) Chronic antidepressant treatment impairs the acquisition of fear extinction. Biol Psychiatry 73:1078\u20131086","journal-title":"Biol Psychiatry"},{"key":"4684_CR15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.neulet.2009.10.049","volume":"468","author":"SA Carmack","year":"2010","unstructured":"Carmack SA, Wood SC, Anagnostaras SG (2010) Amphetamine and extinction of cued fear. Neurosci Lett 468:18\u201322","journal-title":"Neurosci Lett"},{"key":"4684_CR16","doi-asserted-by":"publisher","first-page":"E196","DOI":"10.1208\/aapsj080124","volume":"8","author":"FI Carroll","year":"2006","unstructured":"Carroll FI, Howard JL, Howell LL, Fox BS, Kuhar MJ (2006) Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse. AAPS J 8:E196\u2013E203","journal-title":"AAPS J"},{"key":"4684_CR17","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00221-013-3579-0","volume":"228","author":"BJ Catlow","year":"2013","unstructured":"Catlow BJ, Song S, Paredes DA, Kirstein CL, Sanchez-Ramos J (2013) Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Exp Brain Res 228:481\u2013491","journal-title":"Exp Brain Res"},{"key":"4684_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0166-4328(01)00471-5","volume":"133","author":"D Chaudhury","year":"2002","unstructured":"Chaudhury D, Colwell CS (2002) Circadian modulation of learning and memory in fear-conditioned mice. Behav Brain Res 133:95\u2013108","journal-title":"Behav Brain Res"},{"key":"4684_CR19","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1038\/sj.bjp.0701325","volume":"121","author":"D Crespi","year":"1997","unstructured":"Crespi D, Mennini T, Gobbi M (1997) Carrier-dependent and Ca(2+)-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylendioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine. Br J Pharmacol 121:1735\u20131743","journal-title":"Br J Pharmacol"},{"key":"4684_CR20","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/gbb.12211","volume":"14","author":"T Daldrup","year":"2015","unstructured":"Daldrup T, Remmes J, Lesting J, Gaburro S, Fendt M, Meuth P, Kloke V, Pape HC, Seidenbecher T (2015) Expression of freezing and fear-potentiated startle during sustained fear in mice. Genes Brain Behav 14:281\u2013291","journal-title":"Genes Brain Behav"},{"key":"4684_CR21","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1037\/0003-066X.61.8.741","volume":"61","author":"M Davis","year":"2006","unstructured":"Davis M (2006) Neural systems involved in fear and anxiety measured with fear-potentiated startle. Am Psychol 61:741\u2013756","journal-title":"Am Psychol"},{"key":"4684_CR22","doi-asserted-by":"publisher","first-page":"21626","DOI":"10.3402\/ejpt.v4i0.21626","volume":"4","author":"RA de Kleine","year":"2013","unstructured":"de Kleine RA, Rothbaum BO, van Minnen A (2013) Pharmacological enhancement of exposure-based treatment in PTSD: a qualitative review. Eur J Psychotraumatol 4:21626","journal-title":"Eur J Psychotraumatol"},{"key":"4684_CR23","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.brainres.2016.04.073","volume":"1643","author":"BB de Paula","year":"2016","unstructured":"de Paula BB, Leite-Panissi CR (2016) Distinct effect of 5-HT1A and 5-HT2A receptors in the medial nucleus of the amygdala on tonic immobility behavior. Brain Res 1643:152\u2013158","journal-title":"Brain Res"},{"key":"4684_CR24","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00213-011-2207-6","volume":"215","author":"JP Dougherty","year":"2011","unstructured":"Dougherty JP, Aloyo VJ (2011) Pharmacological and behavioral characterization of the 5-HT2A receptor in C57BL\/6N mice. Psychopharmacology 215:581\u2013593","journal-title":"Psychopharmacology"},{"key":"4684_CR25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/0014-2999(90)94150-V","volume":"191","author":"JL Fitzgerald","year":"1990","unstructured":"Fitzgerald JL, Reid JJ (1990) Effects of methylenedioxymethamphetamine on the release of monoamines from rat brain slices. Eur J Pharmacol 191:217\u2013220","journal-title":"Eur J Pharmacol"},{"key":"4684_CR26","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S0278-5846(82)80180-2","volume":"6","author":"K Fredricson Overo","year":"1982","unstructured":"Fredricson Overo K (1982) Kinetics of citalopram in test animals; drug exposure in safety studies. Prog Neuro-Psychopharmacol Biol Psychiatry 6:297\u2013309","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"4684_CR27","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1124\/pr.55.3.3","volume":"55","author":"AR Green","year":"2003","unstructured":"Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, \u201cecstasy\u201d). Pharmacol Rev 55:463\u2013508","journal-title":"Pharmacol Rev"},{"key":"4684_CR28","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/02791072.1986.10472364","volume":"18","author":"G Greer","year":"1986","unstructured":"Greer G, Tolbert R (1986) Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 18:319\u2013327","journal-title":"J Psychoactive Drugs"},{"key":"4684_CR29","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1046\/j.1471-4159.1996.66010243.x","volume":"66","author":"GA Gudelsky","year":"1996","unstructured":"Gudelsky GA, Nash JF (1996) Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J Neurochem 66:243\u2013249","journal-title":"J Neurochem"},{"key":"4684_CR30","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1038\/npp.2015.318","volume":"41","author":"O Gunduz-Cinar","year":"2016","unstructured":"Gunduz-Cinar O, Flynn S, Brockway E, Kaugars K, Baldi R, Ramikie TS, Cinar R, Kunos G, Patel S, Holmes A (2016) Fluoxetine facilitates fear extinction through amygdala endocannabinoids. Neuropsychopharmacology 41:1598\u20131609","journal-title":"Neuropsychopharmacology"},{"key":"4684_CR31","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1177\/0269881108094650","volume":"23","author":"F Hasler","year":"2009","unstructured":"Hasler F, Studerus E, Lindner K, Ludewig S, Vollenweider F (2009) Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA. J Psychopharmacol 23:923\u2013935","journal-title":"J Psychopharmacol"},{"key":"4684_CR32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/0014-2999(90)90555-K","volume":"177","author":"CR Hekmatpanah","year":"1990","unstructured":"Hekmatpanah CR, Peroutka SJ (1990) 5-hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine-releasing effect of 3,4-methylenedioxymethamphetamine and related agents. Eur J Pharmacol 177:95\u201398","journal-title":"Eur J Pharmacol"},{"key":"4684_CR33","doi-asserted-by":"publisher","first-page":"454","DOI":"10.4236\/jbbs.2012.24053","volume":"2","author":"CR Hughes","year":"2012","unstructured":"Hughes CR, Tran T, Keele NB (2012) 5-HT2A receptor activation normalizes exaggerated fear behavior in p-chlorophenylalanine (PCPA)-treated rats. J Behav Brain Sci 2:454\u2013462","journal-title":"J Behav Brain Sci"},{"key":"4684_CR34","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.brainresbull.2011.06.011","volume":"86","author":"GE Hunt","year":"2011","unstructured":"Hunt GE, McGregor IS, Cornish JL, Callaghan PD (2011) MDMA-induced c-Fos expression in oxytocin-containing neurons is blocked by pretreatment with the 5-HT-1A receptor antagonist WAY 100635. Brain Res Bull 86:65\u201373","journal-title":"Brain Res Bull"},{"key":"4684_CR35","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/clpt.2011.78","volume":"90","author":"CM Hysek","year":"2011","unstructured":"Hysek CM, Simmler LD, Ineichen M, Grouzmann E, Hoener MC, Brenneisen R, Huwyler J, Liechti ME (2011) The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (\u201cecstasy\u201d) in humans. Clin Pharmacol Ther 90:246\u2013255","journal-title":"Clin Pharmacol Ther"},{"key":"4684_CR36","doi-asserted-by":"publisher","first-page":"e36476","DOI":"10.1371\/journal.pone.0036476","volume":"7","author":"CM Hysek","year":"2012","unstructured":"Hysek CM, Simmler LD, Nicola VG, Vischer N, Donzelli M, Krahenbuhl S, Grouzmann E, Huwyler J, Hoener MC, Liechti ME (2012) Duloxetine inhibits effects of MDMA (\u201cecstasy\u201d) in vitro and in humans in a randomized placebo-controlled laboratory study. PLoS One 7:e36476","journal-title":"PLoS One"},{"key":"4684_CR37","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1136\/emj.2009.079905","volume":"27","author":"CM Hysek","year":"2010","unstructured":"Hysek CM, Vollenweider FX, Liechti ME (2010) Effects of a beta-blocker on the cardiovascular response to MDMA (ecstasy). Emerg Med J: EMJ 27:586\u2013589","journal-title":"Emerg Med J: EMJ"},{"key":"4684_CR38","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.neuropharm.2007.12.001","volume":"54","author":"KA Jennings","year":"2008","unstructured":"Jennings KA, Sheward WJ, Harmar AJ, Sharp T (2008) Evidence that genetic variation in 5-HT transporter expression is linked to changes in 5-HT2A receptor function. Neuropharmacology 54:776\u2013783","journal-title":"Neuropharmacology"},{"key":"4684_CR39","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.euroneuro.2013.01.003","volume":"23","author":"L Karlsson","year":"2013","unstructured":"Karlsson L, Carlsson B, Hiemke C, Ahlner J, Bengtsson F, Schmitt U, Kugelberg FC (2013) Altered brain concentrations of citalopram and escitalopram in P-glycoprotein deficient mice after acute and chronic treatment. Eur Neuropsychopharmacology: J Eur Coll Neuropsychopharmacology 23:1636\u20131644","journal-title":"Eur Neuropsychopharmacology: J Eur Coll Neuropsychopharmacology"},{"key":"4684_CR40","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1126\/science.1214592","volume":"334","author":"NN Karpova","year":"2011","unstructured":"Karpova NN, Pickenhagen A, Lindholm J, Tiraboschi E, Kulesskaya N, Agustsdottir A, Antila H, Popova D, Akamine Y, Bahi A, Sullivan R, Hen R, Drew LJ, Castren E (2011) Fear erasure in mice requires synergy between antidepressant drugs and extinction training. Science 334:1731\u20131734","journal-title":"Science"},{"key":"4684_CR41","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0022-3565(25)12956-X","volume":"277","author":"JH Kehne","year":"1996","unstructured":"Kehne JH, Baron BM, Carr AA, Chaney SF, Elands J, Feldman DJ, Frank RA, van Giersbergen PL, McCloskey TC, Johnson MP, McCarty DR, Poirot M, Senyah Y, Siegel BW, Widmaier C (1996) Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 277:968\u2013981","journal-title":"J Pharmacol Exp Ther"},{"key":"4684_CR42","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.pbb.2008.03.032","volume":"90","author":"HL Kimmel","year":"2008","unstructured":"Kimmel HL, Negus SS, Wilcox KM, Ewing SB, Stehouwer J, Goodman MM, Votaw JR, Mello NK, Carroll FI, Howell LL (2008) Relationship between rate of drug uptake in brain and behavioral pharmacology of monoamine transporter inhibitors in rhesus monkeys. Pharmacol Biochem Behav 90:453\u2013462","journal-title":"Pharmacol Biochem Behav"},{"key":"4684_CR43","doi-asserted-by":"crossref","first-page":"423","DOI":"10.31887\/DCNS.2011.13.4\/nkoen","volume":"13","author":"N Koen","year":"2011","unstructured":"Koen N, Stein DJ (2011) Pharmacotherapy of anxiety disorders: a critical review. Dialogues Clin Neurosci 13:423\u2013437","journal-title":"Dialogues Clin Neurosci"},{"key":"4684_CR44","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/bjp.2008.243","volume":"155","author":"M Kreilgaard","year":"2008","unstructured":"Kreilgaard M, Smith DG, Brennum LT, Sanchez C (2008) Prediction of clinical response based on pharmacokinetic\/pharmacodynamic models of 5-hydroxytryptamine reuptake inhibitors in mice. Br J Pharmacol 155:276\u2013284","journal-title":"Br J Pharmacol"},{"key":"4684_CR45","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1046\/j.1471-4159.1997.68052032.x","volume":"68","author":"R Kuczenski","year":"1997","unstructured":"Kuczenski R, Segal DS (1997) Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 68:2032\u20132037","journal-title":"J Neurochem"},{"key":"4684_CR46","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/mp.2013.97","volume":"19","author":"C Lanteri","year":"2014","unstructured":"Lanteri C, Doucet EL, Hernandez Vallejo SJ, Godeheu G, Bobadilla AC, Salomon L, Lanfumey L, Tassin JP (2014) Repeated exposure to MDMA triggers long-term plasticity of noradrenergic and serotonergic neurons. Mol Psychiatry 19:823\u2013833","journal-title":"Mol Psychiatry"},{"key":"4684_CR47","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S0893-133X(00)00126-3","volume":"23","author":"ME Liechti","year":"2000","unstructured":"Liechti ME, Saur MR, Gamma A, Hell D, Vollenweider FX (2000) Psychological and physiological effects of MDMA (\u201cecstasy\u201d) after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans. Neuropsychopharmacology 23:396\u2013404","journal-title":"Neuropsychopharmacology"},{"key":"4684_CR48","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S0924-977X(00)00086-9","volume":"10","author":"ME Liechti","year":"2000","unstructured":"Liechti ME, Vollenweider FX (2000a) Acute psychological and physiological effects of MDMA (\u201cecstasy\u201d) after haloperidol pretreatment in healthy humans. Eur Neuropsychopharmacology: J Eur Coll Neuropsychopharmacol 10:289\u2013295","journal-title":"Eur Neuropsychopharmacology: J Eur Coll Neuropsychopharmacol"},{"key":"4684_CR49","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/026988110001400313","volume":"14","author":"ME Liechti","year":"2000","unstructured":"Liechti ME, Vollenweider FX (2000b) The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine (\u2018Ecstasy\u2019) in healthy volunteers. J Psychopharmacol (Oxford, England) 14:269\u2013274","journal-title":"J Psychopharmacol (Oxford, England)"},{"key":"4684_CR50","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.neuroscience.2007.01.047","volume":"146","author":"AJ McDonald","year":"2007","unstructured":"McDonald AJ, Mascagni F (2007) Neuronal localization of 5-HT type 2A receptor immunoreactivity in the rat basolateral amygdala. Neuroscience 146:306\u2013320","journal-title":"Neuroscience"},{"key":"4684_CR51","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1176\/appi.ajp.158.1.78","volume":"158","author":"JH Meyer","year":"2001","unstructured":"Meyer JH, Kapur S, Eisfeld B, Brown GM, Houle S, DaSilva J, Wilson AA, Rafi-Tari S, Mayberg HS, Kennedy SH (2001) The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. Am J Psychiatry 158:78\u201385","journal-title":"Am J Psychiatry"},{"key":"4684_CR52","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/0269881110378371","volume":"25","author":"MC Mithoefer","year":"2011","unstructured":"Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R (2011) The safety and efficacy of {+\/\u2212}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol (Oxford, England) 25:439\u2013452","journal-title":"J Psychopharmacol (Oxford, England)"},{"key":"4684_CR53","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1177\/0269881112456611","volume":"27","author":"MC Mithoefer","year":"2013","unstructured":"Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Martin SF, Yazar-Klosinski B, Michel Y, Brewerton TD, Doblin R (2013) Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. J Psychopharmacol (Oxford, England) 27:28\u201339","journal-title":"J Psychopharmacol (Oxford, England)"},{"key":"4684_CR54","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.pnpbp.2005.04.009","volume":"29","author":"KC Morley","year":"2005","unstructured":"Morley KC, Arnold JC, McGregor IS (2005) Serotonin (1A) receptor involvement in acute 3,4-methylenedioxymethamphetamine (MDMA) facilitation of social interaction in the rat. Prog Neuro-Psychopharmacol Biol Psychiatry 29:648\u2013657","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"4684_CR55","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.biopsych.2010.08.014","volume":"68","author":"D Mueller","year":"2010","unstructured":"Mueller D, Bravo-Rivera C, Quirk GJ (2010) Infralimbic D2 receptors are necessary for fear extinction and extinction-related tone responses. Biol Psychiatry 68:1055\u20131060","journal-title":"Biol Psychiatry"},{"key":"4684_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbr.2009.11.025","volume":"208","author":"D Mueller","year":"2010","unstructured":"Mueller D, Cahill SP (2010) Noradrenergic modulation of extinction learning and exposure therapy. Behav Brain Res 208:1\u201311","journal-title":"Behav Brain Res"},{"key":"4684_CR57","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1523\/JNEUROSCI.3248-07.2008","volume":"28","author":"D Mueller","year":"2008","unstructured":"Mueller D, Porter JT, Quirk GJ (2008) Noradrenergic signaling in infralimbic cortex increases cell excitability and strengthens memory for fear extinction. J Neurosci 28:369\u2013375","journal-title":"J Neurosci"},{"key":"4684_CR58","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0092-8674(04)00259-4","volume":"117","author":"CF Murchison","year":"2004","unstructured":"Murchison CF, Zhang XY, Zhang WP, Ouyang M, Lee A, Thomas SA (2004) A distinct role for norepinephrine in memory retrieval. Cell 117:131\u2013143","journal-title":"Cell"},{"key":"4684_CR59","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1124\/jpet.110.166595","volume":"334","author":"KS Murnane","year":"2010","unstructured":"Murnane KS, Fantegrossi WE, Godfrey JR, Banks ML, Howell LL (2010) Endocrine and neurochemical effects of 3,4-methylenedioxymethamphetamine and its stereoisomers in rhesus monkeys. J Pharmacol Exp Ther 334:642\u2013650","journal-title":"J Pharmacol Exp Ther"},{"key":"4684_CR60","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.yhbeh.2011.10.012","volume":"61","author":"KS Murnane","year":"2012","unstructured":"Murnane KS, Kimmel HL, Rice KC, Howell LL (2012) The neuropharmacology of prolactin secretion elicited by 3,4-methylenedioxymethamphetamine (\u201cecstasy\u201d): a concurrent microdialysis and plasma analysis study. Horm Behav 61:181\u2013190","journal-title":"Horm Behav"},{"key":"4684_CR61","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/S0896-6273(02)01064-4","volume":"36","author":"KM Myers","year":"2002","unstructured":"Myers KM, Davis M (2002) Behavioral and neural analysis of extinction. Neuron 36:567\u2013584","journal-title":"Neuron"},{"key":"4684_CR62","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/sj.mp.4001939","volume":"12","author":"KM Myers","year":"2007","unstructured":"Myers KM, Davis M (2007) Mechanisms of fear extinction. Mol Psychiatry 12:120\u2013150","journal-title":"Mol Psychiatry"},{"key":"4684_CR63","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1101\/lm.393906","volume":"13","author":"SD Norrholm","year":"2006","unstructured":"Norrholm SD, Jovanovic T, Vervliet B, Myers KM, Davis M, Rothbaum BO, Duncan EJ (2006) Conditioned fear extinction and reinstatement in a human fear-potentiated startle paradigm. Learn Mem (Cold Spring Harbor, NY) 13:681\u2013685","journal-title":"Learn Mem (Cold Spring Harbor, NY)"},{"key":"4684_CR64","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/da.22331","volume":"32","author":"SA Rauch","year":"2015","unstructured":"Rauch SA, King AP, Abelson J, Tuerk PW, Smith E, Rothbaum BO, Clifton E, Defever A, Liberzon I (2015) Biological and symptom changes in posttraumatic stress disorder treatment: a randomized clinical trial. Depress anxiety 32:204\u2013212","journal-title":"Depress anxiety"},{"key":"4684_CR65","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/sj.npp.1300079","volume":"28","author":"VB Risbrough","year":"2003","unstructured":"Risbrough VB, Brodkin JD, Geyer MA (2003) GABA-A and 5-HT1A receptor agonists block expression of fear-potentiated startle in mice. Neuropsychopharmacology 28:654\u2013663","journal-title":"Neuropsychopharmacology"},{"key":"4684_CR66","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1196\/annals.1301.012","volume":"1008","author":"BO Rothbaum","year":"2003","unstructured":"Rothbaum BO, Davis M (2003) Applying learning principles to the treatment of post-trauma reactions. Ann N Y Acad Sci 1008:112\u2013121","journal-title":"Ann N Y Acad Sci"},{"key":"4684_CR67","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1176\/appi.psychotherapy.2002.56.1.59","volume":"56","author":"BO Rothbaum","year":"2002","unstructured":"Rothbaum BO, Schwartz AC (2002) Exposure therapy for posttraumatic stress disorder. Am J Psychother 56:59\u201375","journal-title":"Am J Psychother"},{"key":"4684_CR68","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1023\/A:1006986824213","volume":"19","author":"C Sanchez","year":"1999","unstructured":"Sanchez C, Hyttel J (1999) Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 19:467\u2013489","journal-title":"Cell Mol Neurobiol"},{"key":"4684_CR69","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1038\/npp.2012.29","volume":"37","author":"EK Sawyer","year":"2012","unstructured":"Sawyer EK, Mun J, Nye JA, Kimmel HL, Voll RJ, Stehouwer JS, Rice KC, Goodman MM, Howell LL (2012) Neurobiological changes mediating the effects of chronic fluoxetine on cocaine use. Neuropsychopharmacology 37:1816\u20131824","journal-title":"Neuropsychopharmacology"},{"key":"4684_CR70","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.pharmthera.2014.12.004","volume":"149","author":"N Singewald","year":"2015","unstructured":"Singewald N, Schmuckermair C, Whittle N, Holmes A, Ressler KJ (2015) Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders. Pharmacol Ther 149:150\u2013190","journal-title":"Pharmacol Ther"},{"key":"4684_CR71","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/mp.2012.4","volume":"18","author":"L Slipczuk","year":"2013","unstructured":"Slipczuk L, Tomaiuolo M, Garagoli F, Weisstaub N, Katche C, Bekinschtein P, Medina JH (2013) Attenuating the persistence of fear memory storage using a single dose of antidepressant. Mol Psychiatry 18:7\u20138","journal-title":"Mol Psychiatry"},{"key":"4684_CR72","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00213-010-2026-1","volume":"213","author":"KS Smith","year":"2011","unstructured":"Smith KS, Meloni EG, Myers KM, Van't Veer A, Carlezon WA Jr, Rudolph U (2011) Reduction of fear-potentiated startle by benzodiazepines in C57BL\/6J mice. Psychopharmacology 213:697\u2013706","journal-title":"Psychopharmacology"},{"key":"4684_CR73","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/chir.530070416","volume":"7","author":"M Strolin Benedetti","year":"1995","unstructured":"Strolin Benedetti M, Frigerio E, Tocchetti P, Brianceschi G, Castelli MG, Pellizzoni C, Dostert P (1995) Stereoselective and species-dependent kinetics of reboxetine in mouse and rat. Chirality 7:285\u2013289","journal-title":"Chirality"},{"key":"4684_CR74","doi-asserted-by":"publisher","first-page":"e40187","DOI":"10.1371\/journal.pone.0040187","volume":"7","author":"JH van Wel","year":"2012","unstructured":"van Wel JH, Kuypers KP, Theunissen EL, Bosker WM, Bakker K, Ramaekers JG (2012) Effects of acute MDMA intoxication on mood and impulsivity: role of the 5-HT2 and 5-HT1 receptors. PLoS One 7:e40187","journal-title":"PLoS One"},{"key":"4684_CR75","doi-asserted-by":"publisher","first-page":"4813","DOI":"10.1074\/jbc.270.9.4813","volume":"270","author":"V Vouret-Craviari","year":"1995","unstructured":"Vouret-Craviari V, Auberger P, Pouyssegur J, Van Obberghen-Schilling E (1995) Distinct mechanisms regulate 5-HT2 and thrombin receptor desensitization. J Biol Chem 270:4813\u20134821","journal-title":"J Biol Chem"},{"key":"4684_CR76","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0022-3565(25)09555-2","volume":"273","author":"BK Yamamoto","year":"1995","unstructured":"Yamamoto BK, Nash JF, Gudelsky GA (1995) Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. J Pharmacol Exp Ther 273:1063\u20131070","journal-title":"J Pharmacol Exp Ther"},{"key":"4684_CR77","doi-asserted-by":"publisher","first-page":"e634","DOI":"10.1038\/tp.2015.138","volume":"5","author":"MB Young","year":"2015","unstructured":"Young MB, Andero R, Ressler KJ, Howell LL (2015) 3,4-Methylenedioxymethamphetamine facilitates fear extinction learning. Transl Psychiatry 5:e634","journal-title":"Transl Psychiatry"},{"key":"4684_CR78","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.neuropharm.2012.06.007","volume":"64","author":"G Zhang","year":"2013","unstructured":"Zhang G, Asgeirsdottir HN, Cohen SJ, Munchow AH, Barrera MP, Stackman RW Jr (2013) Stimulation of serotonin 2A receptors facilitates consolidation and extinction of fear memory in C57BL\/6J mice. Neuropharmacology 64:403\u2013413","journal-title":"Neuropharmacology"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-017-4684-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-017-4684-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-017-4684-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T17:35:00Z","timestamp":1750786500000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-017-4684-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,24]]},"references-count":78,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["4684"],"URL":"https:\/\/doi.org\/10.1007\/s00213-017-4684-8","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,24]]},"assertion":[{"value":"23 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Studies were in accordance with National Institutes of Health guidelines, and all procedures were approved by the Institutional Animal Care and Use Committee at Emory University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M.B.Y. became employed by Shire Pharmaceuticals (Lexington, MA, USA) after completion of the studies described herein. M.B.Y. was supported by a NIH\/NIGMS IRACDA grant K21 GM000680 awarded to Emory University. L.L.H. was supported by NIH\/NIDA K05 DA031246. B.O.R. has funding from Wounded Warrior Project, Department of Defense Clinical Trial Grant No. W81XWH-10-1-1045, \u201cEnhancing Exposure Therapy for PTSD: Virtual Reality and Imaginal Exposure with a Cognitive Enhancer,\u201d National Institute of Mental Health Grant No. 1R01MH094757-01, \u201cProspective Determination of Psychobiological Risk Factors for Posttraumatic Stress,\u201d Brain and Behavior Research Foundation (NARSAD) Distinguished Investigator Grant, \u201cOptimal Dose of early intervention to prevent PTSD,\u201d and McCormick Foundation \u201cBrave Heart: MLB\u2019s Welcome Back Veterans SouthEast Initiative.\u201d Dr. Rothbaum receives royalties from Oxford University Press, Guilford, APPI, and Emory University and received one advisory board payment from Genentech. B.W.D. has received research support from Assurex, Axsome, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, NIMH, Otsuka, Pfizer, and Takeda. He has served as a consultant to Pfizer and Medavante.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}